Dipyaman Ganguly, MBBS, PhD, PhD

Dr. Ganguly was trained as a clinician and then moved to research. He did his first PhD (Biotechnology) from CSIR-IICB in 2006, had his second PhD (Immunology) from UT MD Anderson Cancer Center, USA, in 2010 and after his postdoctoral stint in Columbia University, USA, returned to India in 2013. His research interests are role of dendritic cells in autoreactive inflammatory contexts, molecular regulation of innate immune response and role of mechanical cues in immune cells. Dr. Ganguly is a recipient of National Bioscience Award (DBT, 2018), Merck Young Scientist Award (2019), CDRI Drug Research Award (2018), Swarnajayanti Fellowship (DST, 2017), NASI Scopus Young Scientist Award (2017) and Ramanujan Fellowship (2011). He holds to his credit two granted US patents and several publications in eminent international journals like Journal of Experimental Medicine, Science Translational Medicine, Nature Reviews in Immunology, Nature Immunology, PNAS, Trends in Immunology, Journal of Immunology, Diabetes etc. Recently Dr. Ganguly led a CSIR-sponsored randomised control trial on convalescent plasma therapy in COVID-19 in India and also got interested in the domain of immunopathology of COVID-19.


Autoimmunity: Mechanisms and Spectrum

Dipyaman Ganguly, Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata, India.

Autoimmunity comprises clinical contexts wherein local or systemic tissue damage result from untoward immune activation against the ‘self’. Descriptions of autoimmunities have been quite old in the medical literature, but true nature of the underlying mechanistic details has gradually been elucidated in past decade or so. This also is leading to hitherto unappreciated pathogenetic links between apparently discreet pathologies. Moreover multiomics probing into the pathogenesis is revealing more holistic picture about the diseases as well as novel therapeutic approaches. Finally, recent studies are also increasingly appreciating role of the ‘exposomes’ on autoimmune pathogenesis, perhaps most important being role of gut microbiota underlying the immune dysregulations.